Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bristol's Focused BioPharma Strategy Starts To Pay Off

Executive Summary

While many of the world's leading drug companies have relied on mega-mergers and diversified portfolios to drive growth over the last five years, Bristol-Myers Squibb Co. has taken a different tact, jettisoning non-core businesses, slashing overhead and jobs, and announcing a plan to focus its portfolio solely on biopharma.

Related Content

With The Launch Of Yervoy, Early Signs Of R&D Success For Bristol
As Yervoy Launch Nears, Pricing Of Maintenance Therapy Remains A Key Question
Bristol Basks In Broad Ipilimumab Label, Sets High Price
BMS CEO Jim Cornelius to Retire; Andreotti Named CEO
Bristol Flying Solo As A Pure Biopharma After Mead Johnson Spin Out
Can BMS Deliver on Innovation?
Bristol-Myers Squibb Buys Medarex: Adds Eighth ‘Pearl' To String
Bristol’s Take On Restructuring: Cut $1.5 Bil. In Costs, Try BioPharma Model
Generic Plavix: As Bristol Swoons, Broad Implications
Bristol's Bid for Revival





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts